Sterile Expansion Halo Pharma is expanding into sterile injectable manufacturing in 2026 with ongoing capacity build-out at Whippany New Jersey and Montreal, presenting a direct sales opportunity to pharma companies seeking sterile fill-finish capabilities and end-to-end North American supply chain solutions.

Strategic Partnerships Recent collaboration with Apotex for strategic sterile filling capacity indicates Halo’s openness to co-development and capacity-sharing models, suggesting sales angles around capacity commitments, risk-sharing, and joint development for sterile biologics and small molecules.

Integrated CDMO Halo sits within the Normaco Group alongside Noramco and Purisys, enabling a integrated North American API to finished drug products supply chain, which can be positioned to customers seeking a single vendor for clinical and commercial needs across APIs and dosage forms.

Geographic Footprint With facilities in Whippany (NJ), Montreal, and Mirabel (Canada), Halo offers cross-border manufacturing capabilities and regionalized supply resilience, making it attractive to multinational clients aiming to diversify manufacturing sites and reduce logistics risk.

Leadership and Growth Leadership additions and site expansions signal rapid growth and a customer-centric sales motion; targeting growth in BFS and complex solid-dose capabilities along with cGMP operations can open up opportunities with pharma and healthcare manufacturers needing scalable, compliant manufacturing partners.